



UNITED STATES PATENT AND TRADEMARK OFFICE

c10

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/965,807	10/01/2001	Reuben Matalon	SHUTT-1 C1	3645
23599	7590	06/15/2005	EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201			MAYER, SUZANNE MARIE	
			ART UNIT	PAPER NUMBER
			1653	

DATE MAILED: 06/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

06082005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Please find attached a Supplemental Examiner's Amendment which was authorized by Mr. Richard Lebovitz on June 3, 2005.

Smm
Suzanne M. Mayer

22

SUPPLEMENTAL EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with MR. Richard Lebovitz on June 3, 2005.

The application has been amended as follows:

In claim 67: After "SEQ ID No: 2" insert - - - and that is in a pharmaceutically acceptable buffer. - - -

In claim 70: After "components" insert - - - and is in a pharmaceutically acceptable buffer. - - -

In claim 71: After "proteins" insert - - - and is in a pharmaceutically acceptable buffer. - -

-

In claim 72: After "thereof" insert - - - which is in a pharmaceutically acceptable buffer. - -
- -

In claim 80: After "thereof" insert - - - which is in a pharmaceutically acceptable buffer. -
- -

In claim 81: After "thereof" insert - - - and that is in a pharmaceutically acceptable buffer. - - -

In claim 85: After "claim 67" insert - - - in a pharmaceutically acceptable buffer. - - -

In claim 87: After "claim 71" insert - - - in a pharmaceutically acceptable buffer. - - -

Art Unit: 1653

In claim 88: After "claim 72" insert - - - in a pharmaceutically acceptable buffer. - - -

In claim 89: After "thereof" insert - - - which is in a pharmaceutically acceptable buffer, and - - -

In claim 88: After "SEQ ID No: 2" insert - - - which is in a pharmaceutically acceptable buffer. - - -

2. The following is an examiner's statement of reasons for allowance: A supplemental IDS was submitted by Applicants before paying the Issue Fees (and thus has been considered by the Examiner, see signed and attached PTO-1449) which potentially read on some of the claims. However, by amending the claims to include limitation that the protein was in a pharmaceutically acceptable buffer overcomes the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzanne M. Mayer, Ph.D. whose telephone number is 571-272-2924. The examiner can normally be reached on Monday to Friday, 8.30am to 5.00pm.

Art Unit: 1653


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Smm

SMM

8 June 2005


ROBERT A. WAX
PRIMARY EXAMINER
Art Unit 1653